Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Laëtitia Dahan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5267-6190; OpenAlex author ID A5005521442, A5046581053. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 17

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  3. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  4. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. First author DOI 10.1093/oncolo/oyae079↗
  5. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2208470↗
  6. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  7. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Co-author DOI 10.1038/s41416-021-01624-2↗
  8. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac055↗
  9. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  10. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  11. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  12. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. Last author DOI 10.1097/ftd.0000000000000399↗
  13. Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. Co-author DOI 10.1016/s1499-3872(15)60397-6↗
  14. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Co-author DOI 10.1038/bjc.2015.328↗
  15. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  16. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Last author DOI 10.2217/pgs.13.93↗
  17. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … Co-author DOI 10.1093/annonc/mds135↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 9 shared papers, 2015–2026 · strength 1.10
  2. Julien Taı̈eb · 7 shared papers, 2014–2026 · strength 0.81
  3. Jean–Marc Phelip · 4 shared papers, 2021–2026 · strength 0.63
  4. Pascal R. Hammel · 6 shared papers, 2014–2025 · strength 0.49
  5. Rémy Nicolle · 3 shared papers, 2021–2026 · strength 0.45
  6. Jerome F. Cros · 3 shared papers, 2021–2026 · strength 0.45
  7. Olivier Bouché · 3 shared papers, 2018–2026 · strength 0.41
  8. Raëf Abdallah · 2 shared papers, 2025–2026 · strength 0.40
  9. Isabelle Trouilloud · 2 shared papers, 2025–2026 · strength 0.40
  10. David Malka · 3 shared papers, 2014–2026 · strength 0.37
  11. Pierre Laurent‐Puig · 2 shared papers, 2022–2026 · strength 0.37
  12. Nicolas Williet · 3 shared papers, 2018–2025 · strength 0.33
  13. Louis de Mestier · 2 shared papers, 2018–2026 · strength 0.30
  14. Côme Lepage · 2 shared papers, 2021–2022 · strength 0.26
  15. Lysiane Marthey · 3 shared papers, 2015–2025 · strength 0.26
  16. Shulin Zhao · 1 shared paper, 2026 · strength 0.24
  17. Baiyong Shen · 1 shared paper, 2026 · strength 0.24
  18. Yves Rinaldi · 2 shared papers, 2021–2022 · strength 0.23
  19. Marc F. Giovannini · 3 shared papers, 2012–2022 · strength 0.23
  20. Franck Bonnetain · 3 shared papers, 2014–2025 · strength 0.23
  21. Julie Roques · 2 shared papers, 2021–2022 · strength 0.21
  22. Odile Gayet · 2 shared papers, 2021–2022 · strength 0.21
  23. Magali Svrcek · 2 shared papers, 2021–2022 · strength 0.21
  24. Jean‐Luc Van Laethem · 2 shared papers, 2021–2022 · strength 0.21
  25. Francesco Puleo · 2 shared papers, 2021–2022 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.